Search results
Results from the WOW.Com Content Network
Raloxifene increases bone mineral density in postmenopausal women but decreases it in premenopausal women. [14] In the MORE trial, the risk of vertebral fractures was decreased by 30%, and bone mineral density was increased in the spine (by 2.1% at 60 mg, 2.4% at 120 mg) and femoral neck (2.6% at 60 mg, 2.7% at 120 mg). [ 20 ]
In September 2024, the US Food and Drug Administration (FDA) expanded the indication for ribociclib, in combination with an aromatase inhibitor, for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. [12]
Aromatase inhibitors are a common fertility treatment to treat women with PCOS. A meta-analysis analyzing live birth rates for women with PCOS treated with clomiphene compared to letrozole found that letrozole resulted in higher live birth rates. [11] However, ovulation induction remains an off-label indication, which affects use.
Ribavirin is primarily used to treat chronic hepatitis C and viral hemorrhagic fevers (an orphan indication in most countries). [11] Its efficacy for these purposes has been questioned in light of its Food and Drug Administration boxed warning against its use as monotherapy for chronic hepatitis C.
Possible adverse effects of tibolone include unscheduled vaginal bleeding (OR Tooltip Odds ratio = 2.79; incidence 13–26% more than placebo), an increased risk of breast cancer in women with a history of breast cancer (OR Tooltip Odds ratio = 1.5) although apparently not without a history of breast cancer (OR Tooltip Odds ratio = 0.52), an ...
The weekly schedule is an advantage for women who prefer an oral contraceptive, but find it difficult or impractical to adhere to a daily schedule required by other oral contraceptives. [citation needed] For the first twelve weeks of use, it is advised to take the ormeloxifene pill twice per week. [6]
This provides a good indication for real world effectiveness of vaginal rings as the primary source of contraception, as adherence issues are the main source of contraceptive failures. [35] An additional benefit is that the bleeding pattern of the contraceptive vaginal ring is consistent over a year long period, which has led to lower ...
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. [2] Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1).